David Domek
Oklahoma City, OKNPI 1164473880
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Xeris Pharmaceuticals, Inc. at 52.0% of the total. Reporting peaked in 2021 at $10,902 and has fallen 88.4% since, to $1,266 in 2025.
Across 500 payments — averaging $56.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Xeris Pharmaceuticals, Inc.$15K
- Mannkind Corporation$7K
- Tandem Diabetes Care, Inc.$3K
- AstraZeneca$510
- Insulet Corporation$378
- Advanced Respiratory, Inc$295
- plus $3K from 32 others
Across 2 payments — averaging $1625.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Daiichi Sankyo Inc.$3K
What the payments were for
- Consulting fees$8503%
- Speaking & faculty fees$16,14557%
- Travel & lodging$2,1748%
- Food & beverage$9,20832%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Xeris Pharmaceuticals, Inc. | 105 | $14,769 |
| Mannkind Corporation | 134 | $6,685 |
| Tandem Diabetes Care, Inc. | 41 | $2,702 |
| AstraZeneca | 28 | $510 |
| Insulet Corporation | 25 | $378 |
| Advanced Respiratory, Inc | 17 | $295 |
| Abbott | 9 | $280 |
| Lilly USA, LLC | 23 | $252 |
| Sequel Med Tech, LLC | 6 | $244 |
| Neurocrine Biosciences, Inc. | 10 | $237 |
| Baxter Healthcare | 9 | $190 |
| Amgen(2 entities) | 9 | $185 |
| Philips North America LLC | 10 | $182 |
| Dexcom, Inc. | 7 | $140 |
| Novo Nordisk | 2 | $137 |
| Nestle Healthcare Nutrition Inc. | 7 | $135 |
| Arbor Pharmaceuticals, Inc. | 6 | $122 |
| Aimmune Therapeutics, Inc. | 6 | $115 |
| Zealand Pharma US, Inc. | 5 | $86 |
| Regeneron Healthcare Solutions, Inc. | 3 | $85 |
| Medtronic | 4 | $67 |
| Sobi, Inc | 4 | $66 |
| Biomarin Pharmaceutical Inc. | 3 | $65 |
| Chiesi USA, Inc. | 3 | $56 |
| Tolmar, Inc. | 3 | $55 |
| Genentech USA, Inc. | 3 | $53 |
| Ascendis Pharma Endocrinology Inc | 2 | $50 |
| Sandoz | 3 | $47 |
| Sanofi-aventis U.S. LLC | 3 | $46 |
| Eton Pharmaceuticals, Inc. | 1 | $38 |
| Vivus LLC | 2 | $34 |
| Kyowa Kirin, Inc. | 1 | $25 |
| AbbVie | 1 | $22 |
| Endo USA, Inc. | 1 | $18 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
| Electromed, Inc. | 1 | $12 |
| Circassia Inc. | 1 | $11 |
| Shire North American Group Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GVOKE PFS$13,436
- AFREZZA$5,422
- t:slim X2 Insulin Pump with Control-IQ$1,702
- TWIIST$147
- Ozempic$122
- FREESTYLE LIBRE 3$109
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 15 | $15,079 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $1,030 |
| Hydrocortisone | 24 | $772 |
| Fludrocortisone Acetate | 11 | $170 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $252 | $15,07915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Oklahomaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.